Sanofi SNY presented full results from a pharmacokinetic/pharmacodynamic (PK/PD) study on Toujeo in comparison with insulin degludec for the treatment of type 1 diabetes at the 16th Annual Diabetes Technology Meeting, Bethesda, MD.
The randomized double-blind study on Toujeo (insulin glargine 300 Units/mL) demonstrated an overall flat PK/PD profile and a more evenly distributed exposure over 24 hours in the Toujeo arm, compared to insulin degludec, at both the dose levels (0.4 and 0.6 U/kg/day).
Moreover, Toujeo was found to have a more favorable safety profile than Degludec.
Toujeo is already marketed in the U.S. and EU.
Toujeo continues to perform well in key markets, peaking global sales of €167 million in the third quarter of 2016 on the back of a consistently strong performance in the U.S., where Toujeo now occupies 6.6% of the total basal insulin market.
Zacks Rank & Key Picks
Sanofi currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. ANIK, Cambrex Corp. CBM and Vanda Pharmaceuticals, Inc. VNDA. Each of these stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates have increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has increased 19.4% year to date.
Cambrex’s earnings estimates have increased from $2.46 to $2.55 for 2016 and have increased from $2.91 to $3.06 for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 10.9% year to date.
Vanda’s loss estimates have narrowed from 68 cents per share to 56 cents per share for 2016 while its earnings estimates have increased from 16 cents per share to 17 cents per share for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price surged 77.8% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment